BiotechTube

mavrilimumab

Phase 2/3Completed
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

COVID

Conditions

COVID

Trial Timeline

Jul 28, 2020 → Jan 14, 2022

NCT ID
NCT04447469

About mavrilimumab

mavrilimumab is a phase 2/3 stage product being developed by Kiniksa Pharmaceuticals for COVID. The current trial status is completed. This product is registered under clinical trial identifier NCT04447469. Target conditions include COVID.

What happened to similar drugs?

11 of 20 similar drugs in COVID were approved

Approved (11) Terminated (7) Active (6)
✅mRNA-1283.251 Variant-containing FormulationModernaApproved
✅Icosapent ethylAmarin CorporationApproved
✅bamlanivimabEli LillyApproved
✅AZD1222AstraZenecaApproved
✅AZD1222AstraZenecaApproved
✅COVID-19 vaccine Pfizer (3 doses) + COVID-19 vaccine Pfizer (2 doses) + COVID-19 mRNA Vaccine Moderna (3 doses) + COVID-19 mRNA Vaccine Moderna (2 doses) + COVID-19 mRNA Vaccine Moderna (1 dose)SanofiApproved
✅Rivaroxaban 10 mgBayerApproved

Hype Score Breakdown

Clinical
15
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04447469Phase 2/3Completed

Competing Products

20 competing products in COVID

See all competitors
ProductCompanyStageHype Score
mRNA-1283.251 Variant-containing FormulationModernaApproved
0
mRNA-1283.222ModernaPhase 3
0
COVID-19 VaccineModernaPreclinical
0
mRNA-1083ModernaPhase 3
0
SPIKEVAX (mRNA-1273)ModernaPreclinical
0
Moderna COVID-19 VaccineModernaPreclinical
0
Gam-COVID-VacDr. Reddy's LaboratoriesPhase 2/3
31
AVIGAN + Placebo ComparatorDr. Reddy's LaboratoriesPhase 3
29
Favipiravir + NitazoxanideStrides PharmaPhase 2
35
Human COVID-19 immunoglobulin (pH4) for intravenous injection + PlaceboSinopharmPhase 2
31
Mavrilimumab + PlaceboKiniksa PharmaceuticalsPhase 2
29
Mavrilimumab + PlacebosKiniksa PharmaceuticalsPhase 2
29
Mavrilimumab + PlacebosKiniksa PharmaceuticalsPhase 2
29
Gimsilumab + PlaceboRoivant SciencesPhase 2
32
Icosapent ethylAmarin CorporationApproved
25
Icosapent ethylAmarin CorporationPhase 2
25
Bamlanivimab + Placebo + EtesevimabEli LillyPhase 3
40
GX-03 + Petrolatum ointmentTurn TherapeuticsPhase 2
25
Cytotoxic T LymphocytesTevogen BioPhase 1
19
InfliximabCelltrionPhase 2
35